Millennium Management’s Avidity Biosciences RNAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-2,157,270
Closed -$156M 6285
2025
Q4
$156M Buy
2,157,270
+2,127,647
+7,182% +$137M 0.07% 271
2025
Q3
$1.29M Sell
29,623
-207,368
-88% -$8.38M ﹤0.01% 4415
2025
Q2
$6.73M Buy
236,991
+219,943
+1,290% +$6.56M ﹤0.01% 2673
2025
Q1
$503K Sell
17,048
-6,893
-29% -$215K ﹤0.01% 4805
2024
Q4
$696K Buy
23,941
+5,405
+29% +$226K ﹤0.01% 4483
2024
Q3
$851K Sell
18,536
-106,839
-85% -$4.64M ﹤0.01% 4400
2024
Q2
$5.12M Sell
125,375
-43,216
-26% -$1.24M ﹤0.01% 2708
2024
Q1
$4.3M Sell
168,591
-172,025
-51% -$2.7M ﹤0.01% 3011
2023
Q4
$3.08M Sell
340,616
-399,880
-54% -$2.67M ﹤0.01% 3221
2023
Q3
$4.72M Buy
740,496
+695,356
+1,540% +$5.99M ﹤0.01% 2740
2023
Q2
$501K Buy
+45,140
New +$566K ﹤0.01% 4545
2023
Q1
Sell
-750,445
Closed -$16.7M 6780
2022
Q4
$16.7M Buy
750,445
+711,532
+1,829% +$10.6M 0.01% 1618
2022
Q3
$635K Buy
+38,913
New +$744K ﹤0.01% 4743
2022
Q1
Sell
-19,053
Closed -$453K 7394
2021
Q4
$453K Buy
19,053
+3,693
+24% +$88.2K ﹤0.01% 5138
2021
Q3
$378K Buy
15,360
+7,260
+90% +$158K ﹤0.01% 5618
2021
Q2
$200K Sell
8,100
-84,996
-91% -$1.98M ﹤0.01% 6024
2021
Q1
$2.03M Sell
93,096
-11,120
-11% -$272K ﹤0.01% 3519
2020
Q4
$2.66M Buy
+104,216
New +$3.04M ﹤0.01% 3003
2020
Q3
Sell
-226,044
Closed -$6.39M 4762
2020
Q2
$6.39M Buy
+226,044
New +$6.52M 0.01% 1557

Other funds holding RNAM

Millennium Management's RNAM Position: Q1 2026 in Review

Millennium Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 2,157,270 shares — an estimated $156M sold.

Millennium Management first reported a position in RNAM in Q2 2020 and held it in 19 quarters. The position peaked at $156M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Millennium Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Millennium Management sold 2,157,270 Avidity Biosciences shares in Q1 2026, an estimated $156M.
  • Millennium Management first reported a position in Avidity Biosciences in Q2 2020 and held it in 19 quarters.
  • Millennium Management's Avidity Biosciences position peaked at $156M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.